MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Exicure, Inc. (Nasdaq:XCUR)*
Organization & Developments: Exicure
Parents
Exicure, Inc. (Nasdaq:XCUR)*
Children
*Biopharmaceutical company commercializing spherical nucleic acid (SNA) constructs as gene regulation- and chemo-therapeutics for a variety of diseases, including applications in oncology, dermatology, neurology, and for cardiovascular disorders
*Early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA.
*Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
*Exicure is Formerly Known as AuraSense Therapeuticsis.
*Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets.
*Exicure's lead programs address inflammatory diseases, genetic disorders and oncology.
*Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues.
*SNA technology overcomes the most difficult obstacles to gene regulation: genetic targeting with safe and effective in vivo performance.
2021: Revisiting The Investment Thesis On Exicure
2022: In survival mode, Exicure cuts to the bone — pausing all R&D and chopping headcount by 66%
2023: Exicure's combined CEO, CFO takes lead in search to bail out the biotech_ fiercebiotech
3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs.
AuraSense Therapeutics
Jumps
*Key People: Exicure
Finance & Acquisitions: Exicure